Yongliang Zhang
About Yongliang Zhang
Yongliang Zhang is a Senior Principal Investigator at BeiGene in Shanghai, China, with extensive experience in oncology translational research and clinical biomarker strategy.
Title
Yongliang Zhang holds the title of Senior Principal Investigator at BeiGene, based in Shanghai, China. This role entails spearheading research initiatives and driving scientific discovery in the field of oncology.
Current Position at BeiGene
Since August 1, 2020, Yongliang Zhang has been employed at BeiGene in Shanghai, China, serving as a Senior Principal Investigator. In this capacity, he contributes to the advancement of oncology translational research, with a focus on clinical biomarker strategy.
Previous Role at Gracellbio
Between 2018 and 2020, Yongliang Zhang worked at Gracellbio in Shanghai, China, as an Associate Director. During his two-year tenure, he played a key role in the pre-IND stage development of CAR-T cell products and furthered research in clinical biomarker strategies.
Research Scientist at Moffitt Cancer Center
From 2016 to 2018, Yongliang Zhang served as a Research Scientist at Moffitt Cancer Center in the Tampa/St. Petersburg, Florida area. In this role, he focused on research within the oncology field, bringing his expertise in clinical laboratory assays and disease modeling to the institution.
Post-Doctoral Fellowship at Medical University of South Carolina
Yongliang Zhang engaged in a six-year post-doctoral fellowship at the Medical University of South Carolina in Charleston, from 2010 to 2016. His research concentrated on the biology of cancer, autoimmune diseases, graft-versus-host disease (GVHD), and disease modeling.
Education and Expertise
Yongliang Zhang earned his Doctor of Philosophy (Ph.D.) in Medical Immunology from Zhejiang University, where he studied from 2003 to 2008. Prior to that, he achieved a Bachelor of Medicine (MD equivalent) in Basic Medicine from the same university, studying from 1998 to 2003. He has developed solid expertise in clinical biomarker strategy, oncology translational research, and pre-IND stage development of CAR-T cell products. Additionally, he is proficient in MRD detection, CRS surveillance, and CAR-T persistence.